Un­pack­ing the Aduhelm de­ci­sion, Ver­tex's half full glass, a $525M J&J breakup, and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

By now you have sure­ly read about the FDA’s con­tro­ver­sial ap­proval of Bio­gen’s Alzheimer’s drug and all its re­ver­ber­a­tions. But I’d still rec­om­mend check­ing out the meaty re­cap be­low to make sure you didn’t miss all the an­gles that the End­points team has cov­ered. If you’d rather look ahead, look no fur­ther than our three-day vir­tu­al pan­els next week at BIO, where we will dis­cuss what the new nor­mal means for every part of the in­dus­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER